The Global Generic Drugs Market Will Reach $356.8bn In 2020 Predicts New Visiongain Report

07 September 2018
Pharma

A new report by visiongain predicts that the Global Generics Drugs market will reach $356.8bn in 2020. This forecast and others appear in Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets, published in April 2016. Visiongain is a business information provider based in London, UK.

This report examines the current and future trends in the growing generic drugs market. Population growth and changing demographics with increasing proportions of elderly people in most markets will enhance growth of the market. The rapid emergence of the middle-class in many emerging markets will also contribute to growth. Cost-pressures that encourage healthcare providers and governments to introduce policies to further encourage the use of generic drugs will further bring growth to the generics market over the years.
In this report, we examine in detail the global generic drugs market, and provide analyses and forecasts for regional and national markets. Historical revenues, where available, have also been added to strengthen our analysis and demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.

Visiongain’s report provides revenue forecasts to 2026 for the Generic Drugs market, including forecasts for leading regional and national markets: US, EU5 (Germany, UK, France, Italy and Spain), Asia-Pacific (China, Japan and India) as well as emerging markets (Brazil, Russia, Mexico, South Korea and Turkey). The report also discusses selected leading companies in the market. These companies include Teva, Mylan, Novartis (Sandoz), Sun Pharma, Pfizer, Abbott, Allergan, Fresenius Kabi, Sanofi and Aspen.

Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever